In vitro biliary clearance of angiotensin II receptor blockers and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in sandwich-cultured rat hepatocytes: Comparison with in vivo biliary clearance

Journal of Pharmacology and Experimental Therapeutics

Volumn 326, Issue 3, 2008, Pages 983-990

  Abe, Koji ^a   Bridges, Arlene S ^a   Yue, Wei ^a   Brouwer, Kim L R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BROMSULFOPHTHALEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 2; OLMESARTAN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; VALSARTAN; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A; ACYL COENZYME A; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR;

ANIMAL CELL; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG STRUCTURE; DRUG UPTAKE; IMMUNOBLOTTING; IN VITRO STUDY; INCUBATION TIME; LIVER CELL CULTURE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL SURVIVAL; COMPARATIVE STUDY; DRUG EFFECTS; HEPATOBILIARY SYSTEM; LIVER CELL; METABOLIC CLEARANCE RATE; METABOLISM; PHYSIOLOGY; WISTAR RAT;

ACYL COENZYME A; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; BILIARY TRACT; CELL SURVIVAL; CELLS, CULTURED; HEPATOCYTES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METABOLIC CLEARANCE RATE; RATS; RATS, WISTAR; RECEPTORS, ANGIOTENSIN;

EID: 53849092394     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.138073     Document Type: Article

References (37)

1. Basile JN and Chrysant S (2006) The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. J Hum Hypertens 20:169-175.
2. Bow DA, Perry JL, Miller DS, Pritchard JB, and Brouwer KLR (2008) Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in freshly isolated rat hepatocytes. Drug Metab Dispos 36:198-202.
3. Brousil JA and Burke JM (2003) Olmesartan medoxomil: an angiotensin II-receptor blocker. Clin Ther 25:1041-1055.
4. Chandra P and Brouwer KLR (2004) The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharmacol Res 21:719-735.
5. Fujino H, Saito T, Ogawa S, and Kojima J (2005) Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol 57:1305-1311.
6. Fujino H, Yamada I, Shimada S, Yoneda M, and Kojima J (2003) Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica 33:27-41.
7. Fukuda H, Ohashi R, Tsuda-Tsukimoto M, and Tamai I (2008) Effect of plasma protein binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes. Drug Metab Dispos 36:1275-1282.
8. Ghibellini G, Vasist LS, Leslie EM, Heizer WD, Kowalsky RJ, Calvo BF, and Brouwer KLR (2007) In vitro-in vivo correlation of hepatobiliary drug clearance in humans. Clin Pharmacol Ther 81:406-413.
9. Groothuis GM, Hulstaert CE, Kalicharan D, and Hardonk MJ (1981) Plasma membrane specialization and intracellular polarity of freshly isolated rat hepatocytes. Eur J Cell Biol 26:43-51.
10. Hagenbuch B, Stieger B, Foguet M, Lübbert H, and Meier PJ (1991) Functional expression cloning and characterization of the hepatocyte Na +/bile acid cotransport system. Proc Natl Acad Sci U S A 88:10629-10633.
11. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, and Sugiyama Y (2005) Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68:800-807.
12. Hirano M, Maeda K, Shitara Y, and Sugiyama Y (2004) Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139-146.
13. Hoffmaster KA, Turncliff RZ, LeCluyse EL, Kim RB, Meier PJ, and Brouwer KLR (2004) P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. Pharmacol Res 21:1294-1302.
14. Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, and Brouwer KLR (2005) Multiple transport systems mediate the hepatic uptake and biliary excretion of the metabolically stable opioid peptide [D-penicillamine2,5]enkephalin. Drug Metab Dispos 33:287-293.
15. Huang L, Wang Y, and Grimm S (2006) ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34:738-742.
16. Johnson BM, Zhang P, Schuetz JD, and Brouwer KLR (2006) Characterization of transport protein expression in multidrug resistance-associated protein (Mrp) 2-deficient rats. Drug Metab Dispos 34:556-562.
17. Kitamura S, Maeda K, and Sugiyama Y (2005) Involvement of transporters in the hepatic transport of rosuvastatin. Drug Metab Rev 37 (Suppl 2):59-60.
18. Kojima J, Fujino H, Abe H, Yosimura M, Kanda H, and Kimata H (1999) Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile. Biol Pharm Bull 22:142-150.
19. Lam JL, Okochi H, Huang Y, and Benet LZ (2006) In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab Dispos 34:1336-1344.
20. Liu X, Chism JP, LeCluyse EL, Brouwer KR, and Brouwer KLR (1999a) Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos 27:637-644.
21. Liu X, LeCluyse EL, Brouwer KR, Gan LS, Lemasters JJ, Stieger B, Meier PJ, and Brouwer KLR (1999b) Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am J Physiol Gastrointest Liver Physiol 277:G12-G21.
22. Liu X, LeCluyse EL, Brouwer KR, Lightfoot RM, Lee JI, and Brouwer KLR (1999c) Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J Pharmacol Exp Ther 289:1592-1599.
23. Morikawa A, Goto Y, Suzuki H, Hirohashi T, and Sugiyama Y (2000) Biliary excretion of 17beta-estradiol 17beta-D-glucuronide is predominantly mediated by cMOAT/MRP2. Pharmacol Res 17:546-552.
24. Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T, and Ikeda T (2006) OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos 34:862-869.
25. Nezasa K, Higaki K, Takeuchi M, Nakano M, and Koike M (2003) Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobiotica 33:379-388.
26. Seglen PO (1976) Preparation of isolated rat liver cells. Methods Cell Biol 13:29-83.
27. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, and Endou H (1998) Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett 429:179-182.
28. Shitara Y, Horie T, and Sugiyama Y (2006) Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425-446.
29. Shitara Y and Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112:71-105.
30. Talamini MA, Kappus B, and Hubbard A (1997) Repolarization of hepatocytes in culture. Hepatology 25:167-172.
31. Tokui T, Nakai D, Nakagomi R, Yawo H, Abe T, and Sugiyama Y (1999) Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, Oatp2. Pharmacol Res 16:904-908.
32. Trauner M and Boyer JL (2003) Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 83:633-671.
33. Turncliff RZ, Hoffmaster KA, Kalvass JC, Pollack GM, and Brouwer KLR (2006) Hepatobiliary disposition of a drug/metabolite pair: comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes. J Pharmacol Exp Ther 318:881-889.
34. Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, and Sugiyama Y (2006) Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 34:1247-1254.
35. Yamazaki M, Akiyama S, Niinuma K, Nishigaki R, and Sugiyama Y (1997) Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos 25:1123-1129.
36. Yamazaki M, Suzuki H, Hanano M, Tokui T, Komai T, and Sugiyama Y (1993) Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol Gastrointest Liver Physiol 264:G36-G44.
37. Zhang P, Tian X, Chandra P, and Brouwer KLR (2005) Role of glycosylation in trafficking of mrp2 in sandwich-cultured rat hepatocytes. Mol Pharmacol 67:1334-1341.